


C3
wt piglets are weighed once a week. Rectal temperatures are recorded on days 17, 21, 22, 24, 27, 29, 31, 34, 37, 41, 44. Day 44 fecal swabs are collected from each piglet for PCV-2 shedding. The virus is detected and quantified by quantitative PCR. Day 45 necropsies are performed and tissue samples are collected for virus isolation.--

Page 30, line one, please change "CLAIMS" to: --We Claim:--.

IN THE CLAIMS:

Please add the following new claims without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents:

Label --12. (New) An immunogenic preparation comprising a complex of: at least one plasmid encoding and expressing *in vivo* in a porcine host an isolated nucleic acid molecule selected from the group consisting of open reading frame (ORF) 1 of porcine circovirus type II (PCV-2), ORF2 of PCV-2, ORF1 of porcine circovirus type I (PCV-1) and ORF2 of PCV-1; and, an adjuvant which comprises a cationic lipid of formula




in which R₁ is a saturated or unsaturated linear aliphatic radical having from 12 to 18 carbon atoms, R₂ is aliphatic radical comprising from 2 to 3 carbon atoms, and X is an hydroxyl or amine group.

13. (New) An immunogenic preparation comprising at least one plasmid encoding and expressing *in vivo* in a porcine host an isolated nucleic acid molecule selected from the group consisting of open reading frame (ORF) 1 of porcine circovirus type II (PCV-2), ORF2 of PCV-2, ORF1 of porcine circovirus type I (PCV-1) and ORF2 of PCV-1; and, an adjuvant comprising a carbomer.

14. (New) An immunogenic preparation comprising at least one plasmid encoding and expressing *in vivo* in a porcine host an isolated nucleic acid molecule selected from the group consisting of open reading frame (ORF) 1 of porcine circovirus type II (PCV-2), ORF2 of

PCV-2, ORF1 of porcine circovirus type I (PCV-1) and ORF2 of PCV-1; and, an adjuvant comprising a polymer having units of the formula:



in which:

R_1 and R_2 , which are identical or different, represent H or CH_3 ;

$x = 0$ or 1 ; and

$y = 1$ or 2 , with $x + y = 2$.

15. (New) The immunogenic preparation according to claim 12, wherein the cationic lipid is N-(2-hydroxyethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-propanammonium (DMRIE).

16. (New) The immunogenic preparation according to claim 15, wherein DMRIE is coupled to a neutral lipid.

17. (New) The immunogenic preparation according to claim 16, wherein DMRIE is coupled to dioleoylphosphatidylethanolamine (DOPE).

Sub e2 18. (New) The immunogenic preparation according to any one of claims 12, 13, 14, 15, 16 or 17 further comprising a porcine cytokine or a plasmid that encodes and expresses a porcine cytokine.

19. (New) The immunogenic preparation according to claim 18, wherein the porcine cytokine is GM-CSF.

Sub e3 20. (New) The immunogenic preparation according to claim 12, 13, or 14, further comprising a plasmid encoding and expressing an immunogen from a porcine pathogenic agent other than PCV-2 or PCV-1.

21. (New) The immunogenic preparation according to any one of claims 12, 13, 14, 15, or 16, wherein the preparation includes at least one plasmid that contains and expresses ORF1 of PCV-2.

22. (New) The immunogenic preparation according to any one of claims 12, 13, 14, 15, or 16, wherein the preparation includes at least one plasmid that contains and expresses ORF2 of PCV-2.

23. (New) The immunogenic preparation according to any one of claims 12, 13, 14, 15, or 16, wherein the preparation includes at least one plasmid that contains and expresses ORF1 and ORF2 of PCV-2.

C4
CONT 24. (New) The immunogenic preparation according to any one of claims 12, 13, 14, 15, or 16, wherein the preparation includes at least one plasmid that contains and expresses ORF1 of PCV-2 and ORF2 of PCV-2.

25. (New) The immunogenic preparation according to any one of claims 12, 13, 14, 15, or 16, wherein the preparation includes at least one plasmid that contains and expresses ORF1 of PCV-1.

26. (New) The immunogenic preparation according to any one of claims 12, 13, 14, 15, or 16, wherein the preparation includes at least one plasmid that contains and expresses ~~ORF2 of PCV-1.~~

27. (New) The immunogenic preparation according to claim 20, wherein the porcine pathogenic agent other than PCV-1 or PCV-2 is selected from the group consisting of Aujeszky's virus, porcine influenza virus, porcine reproductive and respiratory syndrome (PRRS), porcine parvovirus, hog cholera virus and *Actinobacillus pleuropneumoniae*.

28. (New) The immunogenic preparation of claim 17 wherein the DMRIE:DOPE molar ratio ranges from 95:5 to 5:95.

29. (New) The immunogenic preparation of claim 28 wherein the DMRIE:DOPE molar ratio is 1:1.

30. (New) The immunogenic preparation of claim 15 wherein the plasmid:DMRIE weight ratio ranges from 50:1 to 1:10.

31. (New) The immunogenic preparation of claim 15 wherein the plasmid:DMRIE weight ratio ranges from 10:1 to 1:5.

32. (New) The immunogenic preparation of claim 15 wherein the plasmid:DMRIE weight ratio ranges from 1:1 to 1:2.

33. (New) The immunogenic preparation of claim 17 wherein the plasmid:DMRIE-DOPE weight ratio ranges from 50:1 to 1:10.

34. (New) The immunogenic preparation of claim 17 wherein the plasmid:DMRIE-DOPE weight ratio ranges from 10:1 to 1:5.

35. (New) The immunogenic preparation of claim 17 wherein the plasmid:DMRIE-DOPE weight ratio ranges from 1:1 to 1:2.

36. (New) The immunogenic preparation of claim 14 wherein $x=0$ and $y=2$.

37. (New) The immunogenic preparation of claim 18 wherein the preparation includes a plasmid that encodes and expresses a porcine cytokine which is GM-CSF.

38. (New) The immunogenic preparation of claim 27 wherein the immunogen from a porcine pathogenic agent other than PCV-2 or PCV-1 is selected from the group consisting of: glycoprotein gB of Aujeszky's virus, glycoprotein gD of Aujeszky's virus, porcine influenza virus H1N1 haemagglutinin, porcine influenza virus H1N1 nucleoprotein, porcine influenza virus H3N2 haemagglutinin, porcine influenza virus H3N2 nucleoprotein, the immunogen encoded by ORF5 of PRRS, the immunogen encoded by ORF3 of PRRS, the VP2 protein of the porcine parvovirus, the E1 protein of hog cholera virus, the E2 protein of the hog cholera virus, the immunogen encoded by the deleted apxI gene from *Actinobacillus pleuropneumoniae*, the immunogen encoded by the deleted apxII from *Actinobacillus pleuropneumoniae*, and the immunogen encoded by the deleted apxIII gene from *Actinobacillus pleuropneumoniae*.

39. (New) A method for eliciting an immunogenic response in a porcine host against porcine circovirus comprising administering to the porcine host the immunogenic preparation of any one of claim 12, 13, 14, 15 or 16.--

Please cancel claims 1-11, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents.